• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Learn Why The Bull Case For COMPASS Pathways (CMPS) Could Change Following One Year Trial Results

    Simply Wall St·09/14/2026 12:26:07
    Listen to the news
    • COMPASS Pathways reported 52 week Phase 3 COMP005 topline data for COMP360 in treatment resistant depression, with sustained MADRS score reductions, 40% to 45% response rates, about 30% remission and a safety profile consistent with earlier parts of the trial.
    • The Part C open label extension suggests that both first time and repeat 25 mg COMP360 dosing can be associated with year long symptom relief in a sizeable share of this hard to treat patient group, which matters for real world treatment models and resource planning.
    • Attention now turns to how the investment narrative for COMPASS Pathways evolves in light of year long COMP360 durability data from the COMP005 program.
    Spot 39 healthcare AI stocks that, like COMPASS Pathways, are trying to turn complex science into potential long term treatment breakthroughs in hard to treat conditions.

    COMPASS Pathways Investment Narrative Recap

    To be comfortable owning COMPASS Pathways, you need to believe COMP360 can become an approved treatment for difficult mental health conditions and that clinics, payers and patients will use it at scale. The fresh 52 week COMP005 data supports a long duration treatment profile, which directly affects how frequently patients might need to return and how clinics could plan capacity.

    The most important near term catalyst remains the Phase 3 COMP006 readouts and progress on any rolling NDA process. That is where the regulatory path crystallises. The biggest immediate risk remains execution and timing in Phase 3, combined with funding needs if cash burn stays heavy before any commercial revenue starts.

    The September 9 release of the 52 week COMP005 Part C topline results is the announcement that matters most here. It gives investors more detail on response, remission and safety out to one year in treatment resistant depression, which is the horizon payers and interventional psychiatry centers typically focus on when they model real world use.

    For catalysts, this durability dataset now sits alongside COMP006 as part of the evidence package management plans to bring into a rolling filing. That linkage is important for your risk view. If COMP360 ultimately secures approval and reimbursement, the combination of long lasting effect signals and existing Spravato style infrastructure could influence how quickly COMPASS Pathways can scale its early commercial footprint.

    COMPASS Pathways' current analyst narrative points to revenues of US$284.9 million and earnings of US$53.9 million by 2029, from a starting point of no revenue and a loss of US$192.4 million today. That profile implies revenue growth building from zero and an earnings swing of roughly US$246 million from current levels to the 2029 consensus mark.

    Discover why COMPASS Pathways' fair value points to a 70% potential upside from its current price, which could diminish quickly.

    NasdaqGS:CMPS 1-Year Stock Price Chart
    NasdaqGS:CMPS 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate view on COMPASS Pathways leans heavily on the upside catalyst of rapid commercialization. The most optimistic analysts were already modeling US$667.4 million in revenue and US$29.6 million in earnings by 2029, with a very high 332.8x P/E, before this 52 week durability news. That more bullish story could shift again once you see how different experts update their assumptions.

    Explore 3 other COMPASS Pathways fair value estimates, including one that suggests as much as 625% upside from the current price!

    The Verdict Is Yours

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking For More Investment Ideas Beyond COMPASS Pathways?

    If the COMPASS Pathways story has sharpened your thinking about risk, reward and timelines, it can help to compare it with other companies at different stages of maturity. The Simply Wall St screener lets you filter for traits that match your own comfort zone, whether you prefer stability, value or under the radar opportunities.

    • For investors who care most about downside protection and steady balance sheets, start with a 11 resilient stocks with low risk scores that have historically shown lower risk profiles.
    • If quality at a reasonable price is the priority, scan a 32 high quality undervalued stocks that combine stronger fundamentals with more modest valuations.
    • If you prefer earlier stage opportunities with room to grow if the story plays out, then focus on a 15 high quality undiscovered gems that the broader market may not be paying close attention to yet.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.